We are live on ! Find out more
SCM

Silverarc Capital Management Portfolio holdings

AUM $980M
1-Year Est. Return 470.8%
This Fund
S&P 500
This Quarter Est. Return
+56.43%
1 Year Est. Return
+470.8%
3 Year Est. Return
+3,352.06%
5 Year Est. Return
+7,957.7%
10 Year Est. Return
–
AUM
$172M
AUM Growth
–
Cap. Flow
+$152M
Cap. Flow %
88.14%
Top 10 Hldgs %
34.38%
Holding
84
New
84
Increased
–
Reduced
–
Closed
–

Top Buys

Rank Stock Value
1
VCEL icon
Vericel Corp
VCEL
+$6.7M
2
INSM icon
Insmed
INSM
+$6.39M
3
ITCI
Intra-Cellular Therapies Inc.
ITCI
+$5.26M
4
AMYT
Amryt Pharma plc American Depositary Shares
AMYT
+$5.25M
5
DRNA
Dicerna Pharmaceuticals, Inc.
DRNA
+$5.01M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 87.83%
2 Financials 0.36%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GH icon
26
Guardant Health
GH
$20.2B
$2.43M 1.41%
+18,825
New +$2.17M
VSTM icon
27
Verastem
VSTM
$536M
$2.42M 1.41%
+94,646
New +$1.9M
AFMD
28
DELISTED
Affimed
AFMD
$2.33M 1.35%
+40,000
New +$1.88M
RNLX
29
DELISTED
Renalytix plc American Depositary Shares
RNLX
$2.26M 1.31%
+141,253
New +$1.74M
DCPH
30
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$2.2M 1.28%
+38,620
New +$2.29M
HZNP
31
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$2.19M 1.28%
+30,000
New +$2.23M
SRRA
32
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$2.16M 1.26%
+135,000
New +$1.87M
TPTX
33
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
$1.97M 1.14%
+16,131
New +$1.77M
ADMS
34
DELISTED
Adamas Pharmaceuticals
ADMS
$1.91M 1.11%
+440,955
New +$1.89M
CGEN icon
35
Compugen
CGEN
$220M
$1.82M 1.06%
+150,550
New +$2.08M
MORF
36
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$1.73M 1%
+51,433
New +$1.52M
OTIC
37
DELISTED
Otonomy, Inc.
OTIC
$1.71M 0.99%
+263,951
New +$1.2M
TRIL
38
DELISTED
Trillium Therapeutics Inc.
TRIL
$1.62M 0.94%
+110,000
New +$1.59M
ARNA
39
DELISTED
Arena Pharmaceuticals Inc
ARNA
$1.54M 0.89%
+20,000
New +$1.5M
ZYME icon
40
Zymeworks
ZYME
$1.67B
$1.46M 0.85%
+30,834
New +$1.43M
NXTC icon
41
NextCure
NXTC
$20.5M
$1.42M 0.82%
+10,833
New +$1.4M
BHVN
42
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$1.41M 0.82%
+16,500
New +$1.4M
CLDX icon
43
Celldex Therapeutics
CLDX
$3.02B
$1.41M 0.82%
+80,282
New +$1.44M
SGEN
44
DELISTED
Seagen Inc. Common Stock
SGEN
$1.31M 0.76%
+7,509
New +$1.4M
SRRK icon
45
Scholar Rock
SRRK
$5.87B
$1.21M 0.7%
+25,000
New +$908K
SURF
46
DELISTED
Surface Oncology, Inc. Common Stock
SURF
$1.2M 0.7%
+130,000
New +$1.13M
VRTX icon
47
Vertex Pharmaceuticals
VRTX
$122B
$1.18M 0.69%
+5,000
New +$1.15M
ETNB
48
DELISTED
89bio
ETNB
$1.07M 0.62%
+44,007
New +$1.13M
KDMN
49
DELISTED
Kadmon Holdings, Inc.
KDMN
$1M 0.58%
+241,756
New +$954K
MREO
50
Mereo BioPharma
MREO
$50.3M
$1M 0.58%
+280,000
New +$701K
1
2
3 4

Similar funds

BIP
Blueprint Investment Partners Greensboro, North Carolina $980M AUM 27.19% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $977M AUM 19.09% 1-Year Est. Return
FCM
Fortis Capital Management Bellevue, Washington $977M AUM 17.17% 1-Year Est. Return
KL
KIM LLC Wichita, Kansas $976M AUM 0.91% 1-Year Est. Return
GFP
Gryphon Financial Partners Columbus, Ohio $976M AUM 23.05% 1-Year Est. Return
ADIC
Abu Dhabi Investment Council Abu Dhabi, United Arab Emirates $975M AUM
PCM
Politan Capital Management New York $985M AUM 3.12% 1-Year Est. Return

Silverarc Capital Management's Q4 2020 Portfolio in Review

Q4 2020 is the first quarter with a 13F filing on record for Silverarc Capital Management, which disclosed 84 positions worth $172M. Its ten largest holdings account for 34% of the portfolio.

Its largest position is Vericel Corp: 281,346 shares worth $8.69M.

By sector, the portfolio is most concentrated in Healthcare at 88% of assets, followed by Financials.

  • Silverarc Capital Management's largest Q4 2020 buy was Vericel Corp: 281,346 shares worth $8.69M.
  • Silverarc Capital Management's ten largest holdings make up 34% of its $172M portfolio in Q4 2020.
  • Silverarc Capital Management disclosed 84 positions in Q4 2020, its first 13F filing on record.

Based on Silverarc Capital Management's 13F filing for Q4 2020, filed 16 Feb 2021.